$CGC

Canopy Growth (CGC) reported a 13% year-over-year revenue increase to $58.9M in Q1 2027, with improved margins and reduced losses. However, investors reacted muted due to past disappointments and cash burn concerns. Growth included contributions from the MTL Cannabis acquisition, raising questions about organic growth.

Tilray Brands (TLRY) and Canopy Growth (CGC), two major Canadian cannabis retailers, have seen significant stock declines this year. Tilray reported Q4 revenue of $281.7M, up 25% YoY, with cannabis revenue at $71.5M, up 5% YoY. Canopy reported Q1 revenue of CA$81.2M, up 13% YoY. Tilray has lower net debt and is closer to profitability, while Canopy has higher debt and ongoing EBITDA losses.

Canopy Growth Corp (CGC) filed an SEC Form 4, revealing an insider transaction. On 08/24/2026, 13,344 common shares were disposed of at $1.47 each, with 692,162 shares remaining. The filing was made by Shai Marshall, attorney-in-fact for Christelle Gedeon, an officer of the company.

Curaleaf (CURLF) has made an unsolicited bid for Aurora Cannabis (ACB), offering a 45% premium. Aurora's response was noncommittal. Canopy Growth (CGC) and Tilray Brands (TLRY) are also consolidating, with Tilray expanding into alcohol and CBD. Investors may benefit from acquisitions, but risks include integration challenges and leverage.

Canopy Growth Corporation (CGC) shares rose 15% in a month after reporting Q1 fiscal 2027 earnings that beat estimates, showing revenue growth and improved margins. The company's cannabis business is improving, with increased revenues and narrowing losses. However, cash flow remains a concern, and competition in the cannabis market is stiff. Analysts have slightly improved loss estimates but maintain a 'Hold' rating.

Tilray (TLRY) rose 6% to $4.75, Canopy Growth (CGC) 3% to $1.02, and Aurora Cannabis (ACB) 4% to $3.80, driven by Treasury buybacks lowering yields. Tilray is still down 47% YTD, despite diversification into non-cannabis segments. The cannabis sector's performance varies, with ETFs like MJ and MSOS showing mixed results.

Curaleaf (CURLF) offered to buy Aurora Cannabis (ACB) for $272M, a 45% premium. The deal aims to create a company with $1.5B revenue and $350M EBITDA. Canopy Growth (CGC) may also attract takeover interest due to its global medical cannabis assets and strategic U.S. market exposure, but its complex structure and integration risks are noted.

Guardian Capital LP said it completed the merger of the Guardian i3 Global Quality Growth ETF into the Guardian i3 Global Core Equity Fund. According to the company, ETF series units were exchanged on Aug. 14 and the merged fund’s units were delisted from the Toronto Stock Exchange. CGC shares were last up $0.03 at $67.97.

Curaleaf launched an unsolicited offer to buy Aurora Cannabis for $272 million, or $4 per share, about a 45% premium to Aurora’s 30-day VWAP, aiming for about $1.5 billion revenue, $350 million adjusted EBITDA, and $40 million annual cost synergies. The article also discusses whether Canopy Growth could be a future acquisition target, citing its turnaround and global medical cannabis platform.

Canopy Growth says its Kincardine, Ontario cultivation site received renewed EU-GMP certification from Germany’s Regierungspräsidium Tübingen. The company links the recertification to supplying EU flower from Canada and expanding its EU portfolio after acquiring MTL Cannabis. For Q1 FY2027, Canopy reported $81.2M net revenue, with 22% ($17.6M) from Germany.